Researchers have used a chemical compound to light up treatment-resistant cancers on imaging scans, in a breakthrough that ...

Xcovery Holdings, Inc., an oncology focused pharmaceutical company, today announced that the U.S. Food and Drug Administration (FDA) has approved ensartinib (Ensacove, Xcovery Holdings, Inc.) for the ...

A 36-year-old non-smoking man was not a typical lung cancer patient. Liam Handley, the fit and young resident of Derbyshire ...

The FDA approved ensartinib (Ensacove) as a first-line treatment for adults with ALK-positive locally advanced or metastatic ...

The Food and Drug Administration has approved Ensacove for patients with ALK-positive locally advanced or metastatic ...

Ensartinib has received FDA approval for the first-line treatment of ALK-positive locally advanced or metastatic non–small ...

Researchers at the Icahn School of Medicine at Mount Sinai have identified the mechanism of action of a treatment for ...

Ensartinib has received FDA approval for the first-line treatment of anaplastic lymphoma kinase (ALK)-positive locally ...

The FDA issued a complete response letter for the BLA submission of subcutaneous amivantamab for EGFR-mutated NSCLC, citing ...

Lawmaker says he expects a fight from insurance companies trying to end pre-authorizations. 'The system is kind of a mess for ...

Though lung cancer survival rates are improving, lung cancer is still the leading cause of cancer deaths in the US.

Lung cancer is still one of the most common malignancies with a high global mortality rate with over 2 million cases confirmed by the World Health Organization in 2018. Although there has been ...